For the year ending 2025-12-31, RNGE had $1,942,885 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss on asset disposals of discontinued operations | 0 |
| Gain on disposition of business | 0 |
| Goodwill impairment of discontinued operations | 0 |
| Accounts receivable from discontinued operations | 0 |
| Deposits from discontinued operations | 0 |
| Net income (loss) | 19,167,678 |
| Gain on disposition of asset retirement obligations | 2,444 |
| Gain on sale of fixed assets | 1,085 |
| Fair value of vested stock options | 311,480 |
| Fixed asset impairment | 878,269 |
| Depreciation of property and equipment | 78,383 |
| Amortization of long-term intangible assets | 1,098,737 |
| Accounts receivable | 390,188 |
| Unbilled receivables from discontinued operations | -22,813 |
| Contract assets from discontinued operations | -154,354 |
| Prepaid expenses and other current assets | -13,913 |
| Accounts payable | 580,345 |
| Accounts payable from discontinued operations | -221,442 |
| Accrued expenses | -113,696 |
| Accrued expenses from discontinued operations | -35,496 |
| Cash paid for asset retirement obligations | 1,479,574 |
| Deposits | 15,395 |
| Gain on bargain purchase | 21,928,500 |
| Depreciation of discontinued operations | 91,908 |
| Accretion of asset retirement obligations | 1,912,968 |
| Net cash provided by (used in) operating activities | 123,028 |
| Net proceeds from sale of assets from discontinued operations | 0 |
| Net insurance proceeds from casualty loss from discontinued operations | 0 |
| Net proceeds from disposition of graphium biosciences | 0 |
| Cash paid for equipment purchases | 100,000 |
| Proceeds from asset sales | 492,000 |
| Long-term deposits received | 1,000,000 |
| Net cash provided by investing activities | 1,392,000 |
| Issuance of shares for cash | 1,150,000 |
| Repayment of long-term debt | 522,143 |
| Repayment of line of credit | 200,000 |
| Net cash provided by/ (used in) financing activities | 427,857 |
| Net increase (decrease) in cash and cash equivalents | 1,942,885 |
| Net increase (decrease) in cash and cash equivalents | 1,942,885 |
| Cash and cash equivalents - beginning of period | 167,286 |
| Cash and cash equivalents - end of period | 2,110,171 |
RANGE IMPACT, INC. (RNGE)
RANGE IMPACT, INC. (RNGE)